Kidney Transplant Research Today is a free monthly online journal that collates and summarizes the latest research about Kidney Transplant, including details on risks, prognosis, procedure, surgery, organ donation. | ||||||||
|
African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression.Boardman RE, Alloway RR, Alexander JW, Buell JF, Cardi M, First MR, Hanaway MJ, Munda R, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES Department of Surgery, Division of Transplantation, University of Cincinnati, Cincinnati, OH, USA. African-Americans (AAs) have historically been considered high-risk renal transplant recipients due to increased rejection rates and reduced long-term graft survival. As a result, AAs are often excluded from corticosteroid withdrawal (CSWD) protocols. Modern immunosuppression has reduced rejections and improved graft survival in AAs and may allow successful CSWD. Outcomes in 56 AAs were compared to 56 non-AAs. All patients were enrolled in one of four early CSWD protocols. Results are reported as AA versus non-AA. Acute rejection at 1-year was 23% and 18%; (p = NS); creatinine clearance at 1-year was 75 versus 80 mL/min (p = NS); patient and graft survival was 96% versus 98% and 91% versus 91%; (p = NS). AAs benefit from early CSWD with significantly improved blood pressure, LDL < 130 mg/dL and HDL > 45 mg/dL at 1-year, post-transplant diabetes of 8.7%, and mean weight change at 1-year of 4.8 +/- 7.2 kg. In conclusion, early CSWD in AAs is associated with acceptable rejection rates, excellent patient and graft survival, and improved cardiovascular risk, indicating that the risks and benefits of early CSWD are similar between AAs and non-AAs. Additional follow-up is needed to determine long-term renal function, graft survival, and cardiovascular risk in AAs with early CSWD. Published 12 January 2005 in Am J Transplant, 5(2): 356-65.
© 2004-2008 Kidney Transplant Research Today. All Rights Reserved. |
| ||||||
